Skip to main content
SpringerLink
Log in

Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Luster M, Sherman SI, Skarulis MC et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging 2003; 30:1371–1377.

    Article  CAS  PubMed  Google Scholar 

  2. Pacini F, Molinaro E, Castagna MG et al. Ablation of thyroid residues with 30 mCi131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002; 87:4063–4068.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. División Endocrinología, Hospital de Clínicas José de San Martín, University of Buenos Aires, Argentina

    Fabián Pitoia & Hugo Niepomniszcze

  2. Instituto Argentino de Diagnóstico y Tratamiento, Buenos Aires, Argentina

    Osvaldo J. Degrossi

Authors
  1. Fabián Pitoia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osvaldo J. Degrossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hugo Niepomniszcze
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabián Pitoia.

Additional information

An authors’ reply to this letter is available at http://dx.doi.org/10.1007/s00259-004-1503-3.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pitoia, F., Degrossi, O.J. & Niepomniszcze, H. Why should the radioiodine dose be different in patients with differentiated thyroid carcinoma prepared with recombinant human TSH?. Eur J Nucl Med Mol Imaging 31, 924 (2004). https://doi.org/10.1007/s00259-004-1502-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1502-4

Keywords

Search

Navigation